Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Sep 22, 2025: New investigator-initiated Phase II trial for Efti
Press releases — page 2
New investigator-initiated Phase II trial for Efti
September 21, 2025
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
September 8, 2025
Appendix 4E & 2025 Full Year Statutory Accounts
August 28, 2025
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
August 5, 2025
FDA feedback received for head & neck cancer in CPS below 1
August 4, 2025
Immutep Quarterly Activities Report Q4 FY25
July 30, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
July 29, 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
July 28, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
June 23, 2025
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 27, 2025
Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
May 25, 2025
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
May 15, 2025
High Response Rates achieved in Lung Cancer in INSIGHT-003
May 14, 2025
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
May 5, 2025
Excellent Overall Survival in Head & Neck Cancer Patients
May 4, 2025
Immutep Quarterly Activities Report Q3 FY25
April 29, 2025
Immutep to Participate in Upcoming Investor Conferences
April 2, 2025
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
March 25, 2025
First patient dosed in phase 3 TACTI-004 lung cancer trial
March 24, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
March 20, 2025
Immutep announces initial safety data from IMP761 phase 1
December 16, 2024
Immutep Reports Promising New Data in Head and Neck Cancer
December 11, 2024
Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
December 9, 2024
Excellent Survival Data from INSIGHT-003 Trial in NSCLC
November 13, 2024
Positive Data from Phase II Trial in Soft Tissue Sarcoma
November 13, 2024
Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
October 3, 2024
Immutep receives A$3.6 million French R&D Tax Incentive
September 23, 2024
New Positive Efficacy Data for Efti in Head and Neck Cancer
September 15, 2024
S&P DJI Announces September 2024 Quarterly Rebalance
September 6, 2024
Appendix 4E & 2024 Full Year Statutory Accounts
August 30, 2024
TACTI-003 data selected for oral presentation at ESMO 2024
August 20, 2024
First Participant Dosed in Phase I Study of IMP761
August 13, 2024
Successful Meeting with FDA on Phase III Design in NSCLC
July 21, 2024
Regulatory Clearance received for Phase 1 trial of IMP761
July 16, 2024
Webcast to discuss data presented at ESMO Plenary Session
July 11, 2024
Positive results in TACTI-003 for 1L HNSCC cohort B patients
July 11, 2024
Webcast slides for new Efti clinical data in 1st line HNSCC
June 26, 2024
Positive topline results from ph2b in head & neck cancer
June 26, 2024
Immutep completes underwritten retail entitlement offer
June 24, 2024
Immutep completes institutional pro-rata offer & placement
June 4, 2024
Immutep announces Ph 3 clinical trial collaboration with MSD
June 3, 2024
Immutep Capital Raising Presentation
June 2, 2024
A$100 million fully underwritten equity raising
June 2, 2024
AIPAC-003 safety lead-in data presented at ESMO Breast 2024
May 15, 2024
Positive initial data in phase 2 Soft Tissue Sarcoma trial
May 1, 2024
Positive preliminary topline results from TACTI-003 Cohort B
April 23, 2024
CHDR to conduct first-in-human phase 1 trial of IMP761
April 17, 2024
First Clinical Data announced from 90mg Dosing of Efti
March 5, 2024
PEI provides constructive feedback for ph3 lung cancer trial
December 20, 2023
Immutep receives A$2.6 million French R&D Tax Incentive
December 6, 2023